



US007541329B2

(12) **United States Patent**  
**Bringe et al.**

(10) **Patent No.:** **US 7,541,329 B2**  
(45) **Date of Patent:** **Jun. 2, 2009**

(54) **OIL BODY ASSOCIATED PROTEIN  
COMPOSITIONS AND METHODS OF USE  
THEREOF FOR REDUCING THE RISK OF  
CARDIOVASCULAR DISEASE**

(75) Inventors: **Neal A. Bringe**, St. Charles, MO (US);  
**Kanthasamy Karunanandaa**, Creve  
Coeur, MO (US)

(73) Assignee: **Monsanto Technology LLC**, St. Louis,  
MO (US)

(\*) Notice: Subject to any disclaimer, the term of this  
patent is extended or adjusted under 35  
U.S.C. 154(b) by 399 days.

(21) Appl. No.: **10/511,669**

(22) PCT Filed: **Apr. 17, 2003**

(86) PCT No.: **PCT/US03/12009**

§ 371 (c)(1),

(2), (4) Date: **May 23, 2005**

(87) PCT Pub. No.: **WO03/088749**

PCT Pub. Date: **Oct. 30, 2003**

(65) **Prior Publication Data**

US 2005/0214346 A1 Sep. 29, 2005

#### **Related U.S. Application Data**

(60) Provisional application No. 60/373,460, filed on Apr.  
18, 2002.

(51) **Int. Cl.**

**A61K 38/00** (2006.01)

**A61K 33/00** (2006.01)

**C07K 14/00** (2006.01)

(52) **U.S. Cl.** ..... **514/2**; 424/757; 424/656;  
424/634; 530/300; 530/370; 530/377; 530/378

(58) **Field of Classification Search** ..... 514/2;  
424/757, 656, 634; 530/300, 370, 377, 378  
See application file for complete search history.

(56) **References Cited**

#### **U.S. PATENT DOCUMENTS**

3,642,490	A	2/1972	Hawley et al.	99/17
3,694,221	A	9/1972	Hoer et al.	99/17
4,360,537	A	11/1982	Tan et al.	426/656
5,478,585	A	12/1995	Isono et al.	426/417
5,559,220	A	9/1996	Roessler et al.	536/23.6
5,830,887	A *	11/1998	Kelly	514/182
5,855,892	A	1/1999	Potter	424/757
5,968,516	A *	10/1999	Liu	424/757
6,136,367	A	10/2000	Hoie	424/757
6,171,640	B1	1/2001	Bringe	426/656
2004/0014640	A1 *	1/2004	Kohno et al.	514/2

#### **FOREIGN PATENT DOCUMENTS**

CN	86105538	7/1986
EP	0 533 512	8/2002

EP	1 323 425	A1 *	7/2003
JP	2001-114800		4/2001
JP	2002-101820		4/2002
WO	WO 89/01495		2/1989
WO	WO 00/30602		6/2000
WO	WO 00/30663		6/2000
WO	WO 01/36648		5/2001
WO	WO 02/26243	A1 *	4/2002
WO	WO 02/26788		4/2002

#### **OTHER PUBLICATIONS**

M.C. Berenbaum, Synergy, additivism and antagonism in immunosuppression, A critical review, Clin. Exp. Immunol, 1977, vol. 28, pp. 1-18.\*

M.C. Berenbaum, What is Synergy?, Pharmacological Reviews, 1989, vol. 1969, vol. 41, pp. 93-141.\*

Yamada, et al, Increased clearance of plasma cholesterol after injection of apolipoprotein E into Watanabe heritable hyperlipidemic rabbits, Proc. Natl. Acad. Sci. USA, Jan. 1989, vol. 86, pp. 665-669.\*

Hori, et al., Soy Protein Hydrolyzate with Bound Phospholipids Reduces Serum Cholesterol Levels in Hypercholesterolemic Adult Male Volunteers, Biotechnol. Biochem., 2001, 65(1), pp. 72-78.\*

Lovati, et al/Manzoni, et al, Soybean Protein Products as Regulators of Liver Low-Density Lipoprotein Receptors I Identification of Active Beta-Conglycinin Subunits II Alpha and Alpha' Rich Commercial Soy Concentrate and Alpha' Deficient Mutant Differently Affect Low-Density Lipoprotein Activation, J Agric Food Chem., 1998, V 46, pp. 2474-2484.\*

M. Fiordaliso, et al., Dietary Oligofructose Lower Triglycerides, Phospholipids and Cholesterol in Serum and Very Low Density Lipoproteins of Rats, Lipids, 1995, vol. 30 No. 2, pp. 163-167.\*

J. Wojcicki, et al., Clinical Evaluation of Lecithin as a Lipid-lowering Agent, Phytotherapy Research, Dec. 1995, vol. 9, Iss. 8, pp. 597-599.\*

Tallarida, Ronald J., "Drug Synergism and Dose Effect Data Analysis", (2000) Chapman & Hall/CRC, title page and table of contents provided.\*

(Continued)

*Primary Examiner*—Jon P Weber

*Assistant Examiner*—Abdel A Mohamed

(74) *Attorney, Agent, or Firm*—Chunping Li, Esq.;  
Sonnenschein Nath & Rosenthal LLP

(57) **ABSTRACT**

Compositions and methods for reducing hypercholesterolemia and, accordingly, the risk of cardiovascular disease, are provided. Such compositions may comprise isolated oil body associated proteins. Additionally provided are food-stuffs to which one or more oil body associated proteins have been added. The compositions employed in the invention may further comprise additive compounds, for example, a saponin, an isoflavone, a phospholipid, a carbohydrate substantially resistant to digestion, or a combination thereof. The methods and compositions of the invention may be used to lower cholesterol and other lipid levels in subjects to achieve a reduction in the risk of cardiovascular disease.